The present invention relates to a nasal delivery device for and a method of intranasally delivering substances for systemic uptake, as liquids, such as suspensions or solutions, and powders, where containing medicaments, typically pharmaceuticals, or vaccines.
Referring to
The nasal cavities each comprise a posterior region which is that region which is posterior of the nasal valve NV and an anterior region which is that region which is anterior of the nasal valve NV, as illustrated in
The nasal valve NV comprises the anterior bony cavum which contains inferior turbinate erectile tissue and septal erectile tissue, which are supported respectively by compliant ala tissue and the rigid cartilaginous septum [Cole]. These elements combine to form a dynamic valve, which extends over several millimetres, that adjusts nasal airflow, and is stabilized by cartilage and hone, modulated by voluntary muscle and regulated by erectile tissue. The lumen of the nasal valve NV is the section of narrowest cross-sectional area between the posterior and anterior regions of the nasal airway, and is much longer and narrower dorsally than ventrally, and this lumen defines a triangular entrance which extends to the piriform region of the bony cavum. The nasal valve NV is lined in its anterior part with transitional epithelium, with a gradual transition posterior to respiratory epithelium. The nasal valve NV and anterior vestibule define roughly the anterior one-third of the nose.
The posterior region of the nasal airway is that region which is lined with respiratory epithelium, which is ciliated, and olfactory epithelium, which comprises nerves which extend downwards through the cribiform plate CP from the olfactory bulb, whereas the anterior region of the nasal airway is that region which is lined with squamous epithelium, which is not ciliated, and transitional epithelium, and extends to the skin-lined section at the nares of the nostril. The olfactory epithelium extends on both the lateral and medial sides of the nasal airway, and typically extends downwards about 1.5 to 2.5 cm.
As illustrated in
The upper posterior region is the region above the inferior meatus IM, as illustrated in
As further illustrated in
The upper posterior region is thus that upper posterior region which is bounded by the above-defined vertical and horizontal planes VERT1, HORIZ.
There are many nasal conditions which require treatment. One such condition is nasal inflammation, specifically rhinitis, which can be allergic or non-allergic and is often associated with infection and prevents normal nasal function. By way of example, allergic and non-allergic inflammation of the nasal airway can typically effect between 10 and 20% of the population, with nasal congestion of the erectile tissues of the nasal concha, lacrimation, secretion of watery mucus, sneezing and itching being the most common symptoms. As will be understood, nasal congestion impedes nasal breathing and promotes oral breathing, leading to snoring and sleep disturbance. Other nasal conditions include nasal polyps which arise from the paranasal sinuses, hypertrophic adenoids, secretory otitis media, sinus disease and reduced olfaction.
In the treatment of certain nasal conditions, the topical administration of medicaments is preferable, particularly where the nasal mucosa is the prime pathological pathway, such as in treating or relieving nasal congestion.
Medica meats that are commonly topically delivered include decongestants, anti-histamines, cromoglycates, steroids and antibiotics. At present, among the known anti-inflammatory pharmaceuticals, topical steroids have been shown to have an effect on nasal congestion. Topical decongestants have also been suggested for use in relieving nasal congestion. The treatment of hypertrophic adenoids and chronic secretory otitis media using topical decongestants, steroids and anti-microbial agents, although somewhat controversial, has also been proposed. Further, the topical administration of pharmaceuticals has been used to treat or at least relieve symptoms of inflammation in the anterior region of the nasopharynx, the paranasal sinuses and the auditory tubes.
Medicaments can also be systemically delivered through the nasal pathway, the nasal pathway offering a good administration route for the systemic delivery of pharmaceuticals, such as hormones, for example, oxytocin and calcitonin, and analgetics, such as anti-migraine compositions, as the high blood flow and large surface area of the nasal tissues advantageously provides for rapid systemic uptake.
In relation to systemic delivery, studies [Daley-Yates et al and Harris et al] have shown that significantly increased systemic bio-availability is achieved by delivery as a nasal spray as compared to drops.
Daley-Yates et al investigated the systemic bio-availability of fluticasone propionate where delivered both as an aqueous spray and as nasal drops, and the bio-availability of the nasal spray formulation was about eight times higher than that of the nasal drop formulation. The authors of the this study have attributed this increased bio-availability of the nasal spray formulation to the by-passing of the nose and an increased absorption from the gastro-intestinal (GI) tract, where the nose is by-passed by one or both of mucociliary clearance of the substance or sniffing the substance along the floor of the nose and subsequent swallowing.
Harris et al investigated the intranasal administration of desmopressin as a nasal spray and as nasal drops, and the bio-availability of the nasal spray formulation was two to three times higher than that of the nasal drop formulation.
In line with these studies, the current understanding in the art is that to achieve maximal absorption of substance to the systemic circulation, the substance should be delivered to as large a surface of the nasal cavity as possible.
The present inventors have now contrarily and surprisingly recognized that the delivery of substance to the anterior region of the nasal cavity and an anterior section of the posterior region of the nasal cavity, in particular the anterior third, and more particularly the midanterior third of the posterior region, predominantly influences the systemic bio-availability of the substance, and, by controlling the delivery of the substance to the anterior region of the nasal cavity and the anterior section of the posterior region of the nasal cavity, a more uniform and increased bio-availability can be achieved for a given dose of the substance. A particular problem of existing delivery regimes is the significant variability in the systemic bio-availability, which the present inventors attribute to the significant variation in the distribution of substance as delivered in subject to subject. The present inventors have recognized that delivering the dose of substance in particular to the anterior region of the nasal cavity can provide a desired uniformity to the systemic bio-availability.
Nasal delivery is also expected to be advantageous for the administration of medicaments requiring a rapid onset of action, for example, analgetics, anti-emetics, insulin, anti-epileptics, sedatives and hypnotica, and also other pharmaceuticals, for example, cardio-vascular drugs. It is envisaged that nasal administration will provide for a fast onset of action, at a rate similar to that of injection and at a rate much faster than that of oral administration. Indeed, for the treatment of many acute conditions, nasal administration is advantageous over oral administration, since gastric stasis can further slow the onset of action following oral administration.
It is also expected that nasal delivery could provide an effective delivery route for the administration of proteins and peptides as produced by modern biotechnological techniques. For such substances, the metabolism in the intestines and the first-pass-effect in the liver represent significant obstacles for reliable and cost-efficient delivery.
Furthermore, it is expected that nasal delivery using the nasal delivery technique of the present invention will prove effective in the treatment of many common neurological diseases, such as Alzheimer's, Parkinson's, psychiatric diseases and intracerebral infections, where not possible using existing techniques.
Also, it is expected that the nasal delivery technique of the present invention will allow for the effective delivery of vaccines.
Aside from the delivery of medicaments, the irrigation of the nasal mucosa with liquids, in particular saline solutions, is commonly practised to remove particles and secretions, as well as to improve the mucociliary activity of the nasal mucosa. These solutions can be used in combination with active pharmaceuticals.
For any kind of drug delivery, accurate and reliable dosing is essential, but it is of particular importance in relation to the administration of potent drugs which have a narrow therapeutic window, drugs with potentially serious adverse effects and drugs for the treatment of serious and life-threatening conditions. For some conditions, it is essential to individualize the dosage to the particular situation, for example, in the case of diabetes mellitus. As discussed hereinabove, a particular advantage of the present invention is the reliability in the dosing. This is particularly the case even in the event of a congested nose, such as with a cold or an allergy, as delivery is to the anterior region, which is not congested, though there may be some secretion.
WO-A-00/51672 discloses a delivery device for delivering substance, in particular a medicament, in a bi-directional flow through the nasal cavities, that is, an air flow which passes into one nostril, around the posterior margin of the nasal septum and in the opposite direction out of the other nostril. This bi-directional air flow advantageously acts to stimulate the sensory nerves in the nasal mucosa, thereby conditioning the subject for the delivery and providing a more comfortable delivery situation.
It is an aim of the present invention to provide improved nasal delivery devices and nasal delivery methods, which in particular provide for one or both of increased systemic bio-availability of the delivered substance and improved dose-to-dose uniformity in the systemic bio-availability.
In one aspect the present invention provides a delivery device for delivering a dose of substance for systemic uptake to a nasal cavity of a subject, the delivery device comprising: a nosepiece unit for insertion into a nasal cavity of a subject and comprising an outlet unit which includes at least one nozzle for delivering substance for systemic uptake substantially only to surfaces in one or both of the anterior region and an anterior section of the posterior region of the nasal cavity of the subject; and a substance supply unit which is operable to deliver a dose of substance to the at least one nozzle.
In another aspect the present invention provides a method of delivering a dose of substance for systemic uptake to a nasal cavity of a subject, the method comprising the steps of: disposing a nosepiece unit in the nasal cavity of the subject, the nosepiece unit comprising at least one nozzle for delivering substance for systemic uptake to surfaces substantially only in one or both of the anterior region and an anterior section of the posterior region of the nasal cavity of the subject; and delivering a close of substance from a substance supply unit to the at least one nozzle, such that the substance is delivered to surfaces substantially only in one or both of the anterior region and an anterior section of the posterior region.
Preferred embodiments of the present invention will now be described hereinbelow by way of example only with reference to the accompanying drawings, in which:
The delivery device comprises a housing 15, a nosepiece unit 17 for fitting in a nasal cavity of a subject through which substance is delivered to the nasal cavity, and a substance supply unit 19 which is actuatable to deliver a metered dose of substance to the nosepiece unit 17.
The nosepiece unit 17 comprises an outlet unit 21 which extends into the nasal cavity into which the nosepiece unit 17 is inserted, a first nosepiece member 23, in this embodiment a frusto-conical element, which is disposed to one, proximal end of the outlet unit 21 and is configured to obstruct, in this embodiment close, the nostril into which the nosepiece unit 17 is inserted, a second nosepiece member 25 which is disposed to the other, distal end of the outlet unit 21 and is configured to obstruct, in this embodiment close, the nasal cavity at a position therealong, in this embodiment at a position corresponding substantially to the nasal valve, such as to partition the nasal cavity into a first, anterior region 27 between the first and second nosepiece members 23, 25, which corresponds in volume to about one-third of the nasal cavity, and a second, posterior region 29, which corresponds in volume to about the remaining two-thirds of the nasal cavity, as illustrated in
The outlet unit 21 comprises a support member 31, in this embodiment a narrow, elongate element, to which the first and second nosepiece members 23, 25 are supported, and at least one nozzle 35, in this embodiment a plurality of laterally-directed nozzles 35a, b, disposed between the first and second nosepiece members 23, 25 for delivering substance to the anterior region 27 of the nasal cavity.
In this embodiment the nozzles 35a, b are configured to provide an aerosol spray. In an alternative embodiment the nozzles 35a, b could be configured to deliver jets as columns of substance.
In this embodiment the second nosepiece member 25 comprises a resilient element 37, here in the form of an annular skirt, which through its resilience acts to expand to obstruct the nasal cavity in partitioning the same. In an alternative embodiment the resilient element 37 could take the form of laterally-directed wings, which together act to obstruct the nasal cavity in partitioning the same.
In this embodiment the substance supply unit 19 comprises a mechanical delivery pump, in particular a liquid delivery pump or a powder delivery pump, which delivers metered doses of substance on actuation thereof.
In another alternative embodiment the substance supply unit 19 could comprise a dry powder delivery unit which delivers metered doses of substance, as a dry powder, on actuation thereof.
In yet another alternative embodiment the substance supply unit 19 could comprise an aerosol canister which delivers metered volumes of a propellant, preferably a hydrofluoroalkane (HFA) propellant or the like, containing substance, either as a suspension or solution.
In yet another alternative embodiment the substance supply unit 19 could comprise a nebulizer which delivers metered doses of substance, as an aerosol spray, on actuation thereof.
In this embodiment the substance supply unit 19 is a multi-dose unit for delivering a plurality of metered doses of substance. In another embodiment the substance supply unit 19 could be a single-dose unit for delivering a single metered dose of substance.
In this embodiment the substance supply unit 19 is pre-primeable, here by loading a resilient element, and includes an actuation mechanism 41 which, when triggered, releases the resilient element and actuates the substance supply unit 19 to deliver a metered dose of substance through the nozzles 35a, b of the outlet unit 21.
Operation of the delivery device will now be described hereinbelow with reference to
Referring to
Referring to
The metered dose of substance, in this embodiment in the form of an aerosol spray, is confined to the anterior region 27 of the nasal cavity as defined between the first and second nosepiece members 23, 25. As described hereinabove, the present inventors have recognized that the systemic uptake of substance as delivered via the nasal cavity is, contrary to current thinking, enhanced where delivered through the anterior region of the nasal cavity, and thus, by confining the delivered dose of substance to the anterior region, an enhanced systemic effect is obtained per unit dose of substance as compared to the conventional delivery of substances into the nasal cavity, such as generally by a nasal spray or nasal drops.
Following actuation, as illustrated in
In one embodiment, where the delivery device is a single-dose device, ti device can be discarded.
In another embodiment, where the delivery device is a multi-dose device, the device is ready for further use following priming of the substance supply unit 19. In a preferred embodiment, where the nosepiece unit 17 is replaceable, the nosepiece unit 17 can be replaced with a new nosepiece unit 17.
The delivery device of this embodiment is very similar to the delivery device of the above-described embodiment, and thus, in order to avoid unnecessary duplication of description, only the differences will be described in detail.
The delivery device of this embodiment differs from that of the above-described embodiment in that the support member 31 of the outlet unit 21 includes a gas delivery port 45 which is disposed at a position between the first and second nosepiece members 23, 25, and in further comprising a mouthpiece 47 which is fluidly connected to the gas delivery port 45, such that, on exhalation into the mouthpiece 47, an air flow is delivered to the gas delivery port 45 which acts to develop a pressure in the partitioned anterior region 27 as defined between the first and second nosepiece members 23, 25, which acts to expand the anterior region 27 and thereby promote the delivery of substance thereto.
Operation of the delivery device is illustrated in
In one alternative-embodiment the actuation mechanism 41 could be a breath-actuated mechanism, such that the actuation mechanism 41 acts to actuate the substance supply unit 19 on the generation of a predetermined pressure at the mouthpiece 47.
The delivery device of this embodiment is very similar to the delivery device of the above-described embodiment, and thus, in order to avoid unnecessary duplication of description, only the differences will be described in detail.
The delivery device of this embodiment differs from that of the above-described embodiment in that the support member 31 of the outlet unit 21 includes a gas delivery port 45 which is disposed at a position between the first and second nosepiece members 23, 25, and in further comprising a gas supply unit 49, in this embodiment a compressible bulb, which is fluidly connected to the gas delivery port 45 and actuatable to deliver an air flow to the gas delivery port 45 which acts to develop a pressure in the partitioned anterior region 27 as defined between the first and second nosepiece members 23, 25, which acts to expand the anterior region 27 and thereby promote the delivery of substance thereto.
Operation of the delivery device is illustrated in
The delivery device comprises a housing 115, a nosepiece unit 117 for fitting in a nasal cavity of a subject through which substance is delivered to the nasal cavity, and a substance supply unit 119 which is actuatable to deliver a metered dose of substance to the nosepiece unit 117.
The nosepiece unit 117 comprises an outlet unit 121 which extends into the nasal cavity into which the nosepiece unit 117 is inserted, and a nosepiece member 123, in this embodiment a frusto-conical element, which is disposed to one, proximal end of the outlet unit 121 and is configured to obstruct, in this embodiment close, the nostril into which the nosepiece unit 117 is inserted.
The outlet unit 121 comprises a support member 131, in this embodiment a narrow, elongate element, to which the nosepiece member 123 is supported, and at least one nozzle 135, in this embodiment a plurality of laterally-directed nozzles 135a, b, which is disposed such as to deliver substance substantially entirely to the anterior region 137 of the nasal cavity relative to the posterior region of the nasal cavity 139. By configuring the at least one nozzle 135 such as to direct the substance laterally to the surfaces of the anterior region 137 of the nasal cavity, the substance is substantially entirely delivered to the anterior region 137 of the nasal cavity relative to the posterior region 139 of the nasal cavity.
In this embodiment the nozzles 135a, b are configured to provide an aerosol spray. In an alternative embodiment the nozzles 135a, b could be configured to deliver jets as columns of substance.
In this embodiment the substance supply unit 119 comprises a mechanical delivery pump, in particular a liquid delivery pump or a powder delivery pump, which delivers metered doses of substance on actuation thereof.
In another alternative embodiment the substance supply unit 119 could comprise a dry powder delivery unit which delivers metered doses of substance, as a dry powder, on actuation thereof.
In yet another alternative embodiment the substance supply unit 119 could comprise an aerosol canister which delivers metered volumes of a propellant, preferably a hydrofluoroalkane (HFA) propellant or the like, containing substance, either as a suspension or solution.
In yet another alternative embodiment the substance supply unit 119 could comprise a nebulizer which delivers metered doses of substance, as an aerosol spray, on actuation thereof.
In this embodiment the substance supply unit 119 is a multi-dose unit for delivering a plurality of metered doses of substance. In another embodiment the substance supply unit 119 could be a single-dose unit for delivering a single metered dose of substance.
In this embodiment the substance supply unit 119 is pre-primeable, here by loading a resilient element, and includes an actuation mechanism 141 which, when triggered, releases the resilient element and actuates the substance supply unit 119 to deliver a metered dose of substance through the nozzles 135a, b of the outlet unit 121.
In another embodiment the substance supply unit 119 could be manually actuated, for example, by manually depressing or compressing an applicator element.
Operation of the delivery device will now be described hereinbelow with reference to
Referring to
Referring to
The metered dose of substance, in this embodiment in the form of an aerosol spray, is confined to the anterior region 127 of the nasal cavity. As described hereinabove, the present inventors have recognized that the systemic uptake of substance as delivered via the nasal cavity is, contrary to current thinking, enhanced where delivered through the anterior region 127 of the nasal cavity, and thus, by confining the delivered dose of substance to the anterior region 127, an enhanced systemic effect is obtained per unit dose of substance as compared to the conventional delivery of substances into the nasal cavity, such as generally by a nasal spray or nasal drops.
Following actuation, as illustrated in
In one embodiment, where the delivery device is a single-dose device, the device can be discarded.
In another embodiment, where the delivery device is a multi-dose device, the device is ready for further use following priming of the substance sup ply unit 119. In a preferred embodiment, where the nosepiece unit 117 is replaceable, the nosepiece unit 117 can be replaced with a new nosepiece unit 117.
The delivery device comprises a housing 215, a nosepiece unit 217 for fitting in a nasal cavity of a subject through which substance is delivered to the nasal cavity, a substance supply unit 219 which is actuatable to deliver a metered dose of substance to the nosepiece unit 117, and a mouthpiece unit 2220 through which the subject exhales.
The nosepiece unit 217 comprises an outlet unit 221 which extends into the nasal cavity into which the nosepiece unit 117 is inserted, a first nosepiece member 223, in this embodiment a frusto-conical element, which is disposed to one, proximal end of the outlet unit 221 and is configured to obstruct, in this embodiment close, the nostril into which the nosepiece unit 217 is inserted, a second, expandable nosepiece member 225 which is disposed to the other, distal end of the outlet unit 221 and is configured, when expanded, to obstruct, in this embodiment close, the nasal cavity at a position therealong, in this embodiment at a position corresponding substantially to the nasal valve, such as to partition the nasal cavity into a first, anterior region 227 between the first and second nosepiece members 223, 225, which corresponds in volume to about one-third of the nasal cavity, and a second, posterior region 229, which corresponds in volume to about the remaining two-thirds of the nasal cavity, as illustrated in
The outlet unit 221 comprises a support member 231, in this embodiment a narrow, elongate element, to which the first and second nosepiece members 223, 225 are supported, and at least one nozzle 235, in this embodiment a plurality of laterally-directed nozzles 235a, b, disposed between the first and second nosepiece members 223, 225 for delivering substance to the anterior region 227 of the nasal cavity.
In this embodiment the nozzles 235a, b are configured to provide an aerosol spray. In an alternative embodiment the nozzles 235a, b could be configured to deliver jets as columns of substance.
In this embodiment the second nosepiece member 225 comprises an inflatable member which is fluidly connected to the mouthpiece unit 220, such that, on exhalation by the subject through the mouthpiece unit 220, the second nosepiece member 225 is expanded to obstruct the nasal cavity in partitioning the same.
In this embodiment the substance supply unit 219 comprises a mechanical delivery pump, in particular a liquid delivery pump or a powder delivery pump, which delivers metered doses of substance on actuation thereof.
In another alternative embodiment the substance supply unit 219 could comprise a dry powder delivery unit which delivers metered doses of substance, as a dry powder, on actuation thereof.
In yet another alternative embodiment the substance supply unit 219 could comprise an aerosol canister which delivers metered volumes of a propellant, preferably a hydrofluoroalkane (HFA) propellant or the like, containing substance, either as a suspension or solution.
In yet another alternative embodiment the substance supply unit 219 could comprise a nebulizer which delivers metered doses of substance, as an aerosol spray, on actuation thereof.
In this embodiment the substance supply unit 219 is a multi-dose unit for delivering a plurality of metered doses of substance. In another embodiment the substance supply unit 219 could be a single-dose unit for delivering a single metered dose of substance.
In this embodiment the substance supply unit 219 is pre-primeable, here by loading a resilient element, and includes an actuation mechanism 241 which, when triggered, releases the resilient element and actuates the substance supply unit 219 to deliver a metered dose of substance through the nozzles 235a, b of the outlet unit 221.
In this embodiment the actuation mechanism 241 is a manually-actuated unit, but in another embodiment could be a breath-actuated unit which is actuated in response to the generation of a predetermined pressure at the mouthpiece unit 220, which is sufficient to provide for inflation of the second nosepiece member 225.
Operation of the delivery device will now be described hereinbelow reference to
Referring to
Referring to
Referring to
The metered dose of substance, in this embodiment in the form of an aerosol spray, is confined to the anterior region 227 of the nasal cavity as defined between the first and second nosepiece members 223, 225. As described hereinabove, the present inventors have recognized that the systemic uptake of substance as delivered via the nasal cavity is, contrary to current thinking, enhanced where delivered through the anterior region 227 of the nasal cavity, and thus, by confining the delivered dose of substance to the anterior region 227, an enhanced systemic effect is obtained per unit dose of substance as compared to the conventional delivery of substances into the nasal cavity, such as generally by a nasal spray or nasal drops.
Following actuation, as illustrated in
In one embodiment, where the delivery device is a single-dose device, the device can be discarded.
In another embodiment, where the delivery device is a multi-dose device, the device is ready for further use following priming of the substance supply unit 219. In a preferred embodiment, where the nosepiece unit 217 is replaceable, the nosepiece unit 217 can be replaced with a new nosepiece unit 217.
In one alternative embodiment the second nosepiece member 225 could instead be mechanically expanded, for example, by expandable arm members.
The delivery device comprises a housing 315, a nosepiece unit 317 for fitting in a nasal cavity of a subject through which substance is delivered to the nasal cavity, a substance supply unit 319 which is actuatable to deliver metered doses of first and second substances to the nosepiece unit 317, and a mouthpiece unit 320 through which the subject exhales.
The nosepiece unit 317 comprises an outlet unit 321 which extends into the nasal cavity into which the nosepiece unit 317 is inserted, a first nosepiece member 323, in this embodiment a frusto-conical element, which is disposed to one, proximal end of the outlet unit 321 and is configured to obstruct, in this embodiment close, the nostril into which the nosepiece unit 317 is inserted, a second nosepiece member 325 which is disposed to the other, distal end of the outlet unit 321 and is configured to obstruct, in this embodiment close, the nasal cavity at a position therealong, in this embodiment at a position corresponding substantially to the nasal valve, such as to partition the nasal cavity into a first, anterior region 327 between the first and second nosepiece members 323, 325, which corresponds in volume to about one-third of the nasal cavity, and a second, posterior region 329, which corresponds in volume to about the remaining two-thirds of the nasal cavity, as illustrated in
The outlet unit 321 comprises a support member 331, in this embodiment a narrow, elongate element, to which the first and second nosepiece members 323, 325 are supported, at least one first, anterior nozzle 335, in this embodiment a plurality of laterally-directed anterior nozzles 335a, b, which is disposed between the first and second nosepiece members 323, 325 for delivering substance, in this embodiment substance for systemic application, to the anterior region 327 of the nasal cavity, and at least one second, posterior nozzle 336, in this embodiment a single, axially-directed nozzle, for delivering substance, in this embodiment substance for topical or CNS application, to the posterior region 329 of the nasal cavity.
In this embodiment the anterior nozzles 335a, b are configured to provide an aerosol spray. In an alternative embodiment the anterior nozzles 335a, b could be configured to deliver jets as columns of substance.
In this embodiment the posterior nozzle 336 is configured to provide an aerosol spray. In an alternative embodiment the posterior nozzle 335 could be configured to deliver a jet as a column of substance.
In this embodiment the second nosepiece member 325 comprises a resilient element 337, here in the form of an annular skirt, which through its resilience acts to expand to obstruct the nasal cavity in partitioning the same. In an alternative embodiment the resilient element 337 could take the form of laterally-directed wings, which together act to obstruct the nasal cavity in partitioning the same.
In this embodiment the substance supply unit 319 comprises a mechanical delivery pump, in particular a liquid delivery pump or a powder delivery pump, which delivers metered doses of first and second substances on actuation thereof.
In another alternative embodiment the substance supply unit 319 could comprise a dry powder delivery unit which delivers metered doses of first and second substances, as dry powders, on actuation thereof.
In yet another alternative embodiment the substance supply unit 319 could comprise an aerosol canister which delivers first and second metered volumes of a propellant, preferably a hydrofluoroalkane (HFA) propellant or the like, each containing substance, either as a suspension or solution.
In yet another alternative embodiment the substance supply unit 319 could comprise a nebulizer which delivers metered doses of first and second substances, as aerosol sprays, on actuation thereof.
In this embodiment the substance supply unit 319 is a multi-dose unit for delivering a plurality of metered doses of first and second substances. In another embodiment the substance supply unit 319 could be a single-dose unit for delivering a single metered dose of first and second substances.
In this embodiment the substance supply unit 319 is pre-primeable, here by loading a resilient element, and includes an actuation mechanism 341 which, when triggered, releases the resilient element and actuates the substance supply unit 319 to deliver metered doses of first and second substances through the respective ones of the anterior nozzles 335a, b and posterior nozzle 336 of the outlet unit 321.
Operation of the delivery device will now be described hereinbelow with reference to
Referring to
Referring to
The metered dose of the first substance, in this embodiment in the form of an aerosol spray, is confined to the anterior region 327 of the nasal cavity as defined between the first and second nosepiece members 323, 325. As described hereinabove, the present inventors have recognized that the systemic uptake of substance as delivered via the nasal cavity is, contrary to current thinking, enhanced where delivered through the anterior region 327 of the nasal cavity, and thus, by confining the delivered dose of substance to the anterior region 327, an enhanced systemic effect is obtained per unit dose of substance as compared to the conventional delivery of substances into the nasal cavity, such as generally by a nasal spray or nasal drops.
Following actuation, as illustrated in
In one embodiment, where the delivery device is a single-dose device, the device can be discarded.
In another embodiment, where the delivery device is a multi-dose device, the device is ready for further use following priming of the substance supply unit 319. In a preferred embodiment, where the nosepiece unit 317 is replaceable, the nosepiece unit 317 can be replaced with a new nosepiece unit 317.
The delivery device comprises a housing 415, a nosepiece unit 417 for fitting in a nasal cavity of a subject through which substance is delivered to the nasal cavity, a substance supply unit 419 which is actuatable to deliver a metered dose of substance to the nosepiece unit 417, and a mouthpiece unit 420 through which the subject exhales.
The nosepiece unit 417 comprises a body unit 421 which comprises a first nosepiece member 423, in this embodiment a frusto-conical element, which is disposed at one, proximal end and is configured to obstruct, in this embodiment close, the nostril into which the nosepiece unit 417 is inserted, and a second nosepiece member 425 which is disposed to the other, distal end and comprises a flexible, elongate element which is sufficiently compliant extend into, and in one embodiment, through the nasal valve. The second nosepiece member 425 has a shape, size and surface properties which enable the second nosepiece member 425 comfortably to penetrate the nasal valve. In this embodiment, when the nosepiece unit 417 is fully inserted into a nasal cavity, the distal end of the second nosepiece member 425 extends from about 3 cm to about 5 cm into the nasal cavity.
The nosepiece unit 417 further comprises at least one, in this embodiment a plurality of laterally-directed anterior nozzles 435a, b which are configured such as to deliver substance, in this embodiment substance for systemic application, to surfaces within the anterior region of the nasal cavity, and at least one second, posterior nozzle 435, in this embodiment a single, axially-directed nozzle, for delivering the substance to surfaces in an anterior section of the posterior region of the nasal cavity, in this embodiment an anterior third of the posterior region, and a preferred embodiment a mid-anterior third of the posterior region, as illustrated in
In this embodiment the anterior nozzles 435a, b are configured to provide an aerosol spray. In an alternative embodiment the anterior nozzles 435a, b could be configured to deliver jets as columns of substance.
In this embodiment the posterior nozzle 436 is configured to provide an aerosol spray. In an alternative embodiment the posterior nozzle 436 could be configured to deliver a jet as a column of substance.
In this embodiment the substance supply unit 419 comprises a mechanical delivery pump, in particular a liquid delivery pump or a powder delivery pump, which delivers a metered dose of substance on actuation thereof.
In another alternative embodiment the substance supply unit 419 could comprise a dry powder delivery unit which delivers a metered dose of substance, as a dry powder, on actuation thereof.
In yet another alternative embodiment the substance supply unit 419 could comprise an aerosol canister which delivers a metered volume of a propellant, preferably a hydrofluoroalkane (HFA) propellant or the like, containing substance, either as a suspension or solution.
In yet another alternative embodiment the substance supply unit 419 could comprise a nebulizer which delivers a metered dose of substance, as an aerosol spray, on actuation thereof.
In this embodiment the substance supply unit 419 is a multi-dose unit for delivering a plurality of metered doses of substance. In another embodiment the substance supply unit 419 could be a single-dose unit for delivering a single metered dose of substance.
In this embodiment the substance supply unit 419 is pre-primeable, here by loading a resilient element, and includes an actuation mechanism 441 which, when triggered, releases the resilient element and actuates the substance supply unit 419 to deliver a metered dose of substance through the anterior nozzles 435a, b and the posterior nozzle 436. In this embodiment the actuation mechanism 441 is breath actuated in response to exhalation by the subject through the mouthpiece unit 420.
Operation of the delivery device will now be described hereinbelow with reference to
Referring to
Referring to
The substance as delivered from the anterior nozzles 435a, b is delivered to surfaces in the anterior region of the nasal cavity, and the substance as delivered from the posterior nozzle 436 is delivered to an anterior section of the posterior region of the nasal cavity, in this embodiment the anterior third of the posterior region of the nasal cavity, and more preferably substantially entirely to the mid-anterior third of the posterior region of the nasal cavity. As described hereinabove, the present inventors have recognized that the systemic uptake of substance as delivered via the nasal cavity is, contrary to current thinking, enhanced where delivered through the anterior region of the nasal cavity and the anterior third of the posterior region of the nasal cavity, and thus, by confining the delivered dose of substance to the anterior region and the anterior third of the posterior region of the nasal cavity, an enhanced systemic effect is obtained per unit dose of substance as compared to the conventional delivery of substances into the nasal cavity, such as generally by a nasal spray or nasal drops.
Following actuation, as illustrated in
In one embodiment, where the delivery device is a single-dose device, the device can be discarded.
In another embodiment, where the delivery device is a multi-dose device, the device is ready for further use following priming of the substance supply unit 419. In a preferred embodiment, where the nosepiece unit 417 is replaceable, the nosepiece unit 417 can be replaced with a new nosepiece unit 417.
The delivery device comprises a housing 515, a nosepiece unit 517 for fitting in a nasal cavity of a subject through which substance is delivered to the nasal cavity, and a substance supply unit 519 which is actuatable to deliver a metered dose of substance to the nosepiece unit 517.
The nosepiece unit 517 comprises a body unit 521 which comprises a first nosepiece member 523, in this embodiment a frusto-conical element, which is disposed at one, proximal end and is configured to obstruct, in this embodiment close, the nostril into which the nosepiece unit 517 is inserted, a second nosepiece member 525 which is disposed to the other, distal end and comprises a flexible, elongate element which is sufficiently compliant to extend into, and in one embodiment, through the nasal valve, and a flow channel 527 which is fluidly connected to an actuation mechanism 541 of the substance supply unit 519, as will be described in more detail hereinbelow.
The nosepiece unit 517 further comprises at least one, in this embodiment a plurality of laterally-directed anterior nozzles 535a, b which are configured such as to deliver substance, in this embodiment substance for systemic application, to surfaces within the anterior region of the nasal cavity, and at least one second, posterior nozzle 536, in this embodiment a single, axially-directed nozzle, for delivering the substance to surfaces in an anterior section of the posterior region of the nasal cavity, in this embodiment an anterior third of the posterior region, and a preferred embodiment a mid-anterior third of the posterior region, as illustrated in
In this embodiment the anterior nozzles 535a, b are configured to provide n aerosol spray. In an alternative embodiment the anterior nozzles 535a, b could be configured to deliver jets as columns of substance.
In this embodiment the posterior nozzle 536 is configured to provide an aerosol spray. In an alternative embodiment the posterior nozzle 536 could be configured to deliver a jet as a column of substance.
In this embodiment the substance supply unit 519 comprises a mechanical delivery pump, in particular a liquid delivery pump or a powder delivery pump, which delivers a metered dose of substance on actuation thereof.
In another alternative embodiment the substance supply unit 519 could comprise a dry powder delivery unit which delivers a metered dose of substance, as a dry powder, on actuation thereof.
In yet another alternative embodiment the substance supply unit 519 could comprise an aerosol canister which delivers a metered volume of a propellant, preferably a hydrofluoroalkane (HFA) propellant or the like, containing substance, either as a suspension or solution.
In yet another alternative embodiment the substance supply unit 519 could comprise a nebulizer which delivers a metered dose of substance, as an aerosol spray, on actuation thereof.
In this embodiment the substance supply unit 519 is a multi-dose unit for delivering a plurality of metered doses of substance. In another embodiment the substance supply unit 519 could be a single-dose unit for delivering a single metered dose of substance.
In this embodiment the substance supply unit 519 is pre-primeable, here by loading a resilient element, and includes an actuation mechanism 541 which, when triggered, releases the resilient element and actuates the substance supply unit 519 to deliver a metered dose of substance through the anterior nozzles 535a, b and the posterior nozzle 536. In this embodiment the actuation mechanism 541 is breath actuated in response to nasal exhalation by the subject, which nasal exhalation acts to generate a positive pressure in the nasal cavity, which is fluidly connected to the actuation mechanism 541 by the flow channel 527 of the nosepiece unit 517. The generation of a positive pressure in the nasal cavity also advantageously provides for expansion of the nasal cavity, which facilitates deposition on the surfaces within the nasal cavity.
Operation of the delivery device will now be described hereinbelow with reference to
Referring to
Referring to
The substance as delivered from the anterior nozzles 535a, b is delivered to surfaces in the anterior region of the nasal cavity, and the substance as delivered from the posterior nozzle 536 is delivered to an anterior section of the posterior region of the nasal cavity, in this embodiment the anterior third of the posterior region of the nasal cavity, and more preferably substantially to the mid-anterior third of the posterior region of the nasal cavity. As described hereinabove, the present inventors have recognized that the systemic uptake of substance as delivered via the nasal cavity is, contrary to current thinking, enhanced where delivered through the anterior region of the nasal cavity and the anterior third of the posterior region of the nasal cavity, and thus, by confining the delivered dose of substance to the anterior region and the anterior third of the posterior region of the nasal cavity, an enhanced systemic effect is obtained per unit dose of substance as compared to the conventional delivery of substances into the nasal cavity, such as generally by a nasal spray or nasal drops.
Following actuation, as illustrated in
In one embodiment, where the delivery device is a single-dose device, the device can be discarded.
In another embodiment, where the delivery device is a multi-dose device, the device is ready for further use following priming of the substance supply unit 519. In a preferred embodiment, where the nosepiece unit 417 is replaceable, the nosepiece unit 517 can be replaced with a new nosepiece unit 517.
Finally, it will be understood that the present invention has been described in its preferred embodiments and can be modified in many different ways without departing from the scope of the invention as defined by the appended claims.
For example, in one embodiment the substance could be formulated such as to hinder mucociliary clearance, as would occur from the ciliated mucosal surfaces in the posterior region of the nasal cavity, and also prevent gravitational flow of the substance and dripping out of the substance from the nasal cavity. Typically, the formulation could have adhesive properties, for example, as a thixotropic formulation, and in one embodiment could be formulated in the manner of a gel.
In another embodiment the substance supply units 19, 119, 219, 319, 419, 519 of the above-described embodiments could be configured to deliver a combination of liquid and powdered substances.
Number | Date | Country | Kind |
---|---|---|---|
0605799.6 | Mar 2006 | GB | national |
This application is a continuation of U.S. patent application Ser. No. 15/001,344, filed Jan. 20, 2016, which is a divisional of U.S. patent application Ser. No. 12/293,972, filed Aug. 27, 2009, now U.S. Pat. No. 9,272,104, which is a National Phase Application of International Application No. PCT/IB07/001998, filed on Mar. 23, 2007, which claims the benefit of and priority to Application No, GB 0605799,6, filed on Mar. 23, 2006. The disclosure of each of the above applications is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
605436 | Kellogg | Jun 1898 | A |
642748 | Manners | Feb 1900 | A |
658436 | Groth | Sep 1900 | A |
746749 | Seidel | Dec 1903 | A |
794641 | Ramey | Jul 1905 | A |
902832 | Philbrook | Nov 1908 | A |
5437267 | Weinstein et al. | Aug 1995 | A |
5797390 | McSoley | Aug 1998 | A |
5797392 | Keldmann et al. | Aug 1998 | A |
5901703 | Ohki et al. | May 1999 | A |
6491940 | Levin | Dec 2002 | B1 |
6648848 | Keldmann et al. | Nov 2003 | B1 |
6715485 | Djupesland | Apr 2004 | B1 |
D530815 | Murphy et al. | Oct 2006 | S |
7347201 | Djupesland | Mar 2008 | B2 |
7377901 | Djupesland et al. | May 2008 | B2 |
7469700 | Baran | Dec 2008 | B2 |
7481218 | Djupesland | Jan 2009 | B2 |
7543581 | Djupesland | Jun 2009 | B2 |
7740014 | Djupesland | Jun 2010 | B2 |
7784460 | Djupesland et al. | Aug 2010 | B2 |
7841337 | Djupesland | Nov 2010 | B2 |
7854227 | Djupesland | Dec 2010 | B2 |
7934503 | Djupesland et al. | May 2011 | B2 |
7975690 | Djupesland | Jul 2011 | B2 |
8047202 | Djupesland | Nov 2011 | B2 |
8146589 | Djupesland | Apr 2012 | B2 |
8171929 | Djupesland et al. | May 2012 | B2 |
8327844 | Djupesland | Dec 2012 | B2 |
8511303 | Djupesland | Aug 2013 | B2 |
8522778 | Djupesland | Sep 2013 | B2 |
8550073 | Djupesland | Oct 2013 | B2 |
8555877 | Djupesland | Oct 2013 | B2 |
8555878 | Djupesland | Oct 2013 | B2 |
8590530 | Djupesland et al. | Nov 2013 | B2 |
8596278 | Djupesland | Dec 2013 | B2 |
8800555 | Djupesland | Aug 2014 | B2 |
8875704 | Djupesland et al. | Nov 2014 | B2 |
8899229 | Djupesland et al. | Dec 2014 | B2 |
8910629 | Djupesland et al. | Dec 2014 | B2 |
D723156 | Djupesland et al. | Feb 2015 | S |
D725769 | Djupesland et al. | Mar 2015 | S |
8978647 | Djupesland et al. | Mar 2015 | B2 |
9010325 | Djupesland et al. | Apr 2015 | B2 |
9038630 | Djupesland et al. | May 2015 | B2 |
9067034 | Djupesland et al. | Jun 2015 | B2 |
9072857 | Djupesland | Jul 2015 | B2 |
9108015 | Djupesland | Aug 2015 | B2 |
9119932 | Djupesland | Sep 2015 | B2 |
9132249 | Djupesland | Sep 2015 | B2 |
9144652 | Djupesland et al. | Sep 2015 | B2 |
9168341 | Djupesland | Oct 2015 | B2 |
9205208 | Djupesland | Dec 2015 | B2 |
9205209 | Djupesland | Dec 2015 | B2 |
9272104 | Djupesland | Mar 2016 | B2 |
D759805 | Djupesland | Jun 2016 | S |
D761951 | Djupesland | Jul 2016 | S |
9452272 | Djupesland et al. | Sep 2016 | B2 |
9468727 | Djupesland | Oct 2016 | B2 |
D773644 | Djupesland | Dec 2016 | S |
9522243 | Djupesland | Dec 2016 | B2 |
9566402 | Djupesland | Feb 2017 | B2 |
9649456 | Djupesland et al. | May 2017 | B2 |
D809128 | Djupesland | Jan 2018 | S |
9949923 | Djupesland | Apr 2018 | B2 |
20040024330 | Djupesland et al. | Feb 2004 | A1 |
20040112378 | Djupesland | Jun 2004 | A1 |
20040112379 | Djupesland | Jun 2004 | A1 |
20040112380 | Djupesland | Jun 2004 | A1 |
20040149289 | Djupesland | Aug 2004 | A1 |
20040182388 | Djupesland | Sep 2004 | A1 |
20050028812 | Djupesland | Feb 2005 | A1 |
20050072430 | Djupesland | Apr 2005 | A1 |
20050235992 | Djupesland | Oct 2005 | A1 |
20050281751 | Levin | Dec 2005 | A1 |
20060096589 | Djupesland | May 2006 | A1 |
20060107957 | Djupesland | May 2006 | A1 |
20060169278 | Djupesland et al. | Aug 2006 | A1 |
20060219240 | Djupesland | Oct 2006 | A1 |
20060219241 | Djupesland | Oct 2006 | A1 |
20060225732 | Djupesland | Oct 2006 | A1 |
20060231094 | Djupesland | Oct 2006 | A1 |
20070039614 | Djupesland | Feb 2007 | A1 |
20070125371 | Djupesland | Jun 2007 | A1 |
20070186927 | Djupesland et al. | Aug 2007 | A1 |
20080161771 | Djupesland | Jul 2008 | A1 |
20080163874 | Djupesland | Jul 2008 | A1 |
20080221471 | Djupesland et al. | Sep 2008 | A1 |
20080223363 | Djupesland | Sep 2008 | A1 |
20080289629 | Djupesland et al. | Nov 2008 | A1 |
20090101146 | Djupesland | Apr 2009 | A1 |
20090293873 | Djupesland et al. | Dec 2009 | A1 |
20090304802 | Djupesland et al. | Dec 2009 | A1 |
20090314293 | Djupesland | Dec 2009 | A1 |
20090320832 | Djupesland | Dec 2009 | A1 |
20100035805 | Hafner | Feb 2010 | A1 |
20100051022 | Djupesland et al. | Mar 2010 | A1 |
20100057047 | Djupesland et al. | Mar 2010 | A1 |
20100199984 | Williams et al. | Aug 2010 | A1 |
20100242959 | Djupesland et al. | Sep 2010 | A1 |
20100282246 | Djupesland et al. | Nov 2010 | A1 |
20100288275 | Djupesland et al. | Nov 2010 | A1 |
20100300439 | Djupesland et al. | Dec 2010 | A1 |
20110023869 | Djupesland | Feb 2011 | A1 |
20110053827 | Hafner | Mar 2011 | A1 |
20110088690 | Djupesland et al. | Apr 2011 | A1 |
20110088691 | Djupesland | Apr 2011 | A1 |
20110114087 | Djupesland et al. | May 2011 | A1 |
20110120456 | Immel | May 2011 | A1 |
20110126830 | Djupesland et al. | Jun 2011 | A1 |
20110259329 | Djupesland et al. | Oct 2011 | A1 |
20110318345 | Djupesland | Dec 2011 | A1 |
20120000459 | Djupesland | Jan 2012 | A1 |
20120006323 | Djupesland | Jan 2012 | A1 |
20120073571 | Djupesland | Mar 2012 | A1 |
20120090608 | Djupesland et al. | Apr 2012 | A1 |
20120260915 | Djupesland | Oct 2012 | A1 |
20130098362 | Djupesland et al. | Apr 2013 | A1 |
20130125889 | Djupesland et al. | May 2013 | A1 |
20130327320 | Djupesland | Dec 2013 | A1 |
20140018295 | Djupesland | Jan 2014 | A1 |
20140041660 | Djupesland et al. | Feb 2014 | A1 |
20140060536 | Djupesland | Mar 2014 | A1 |
20140073562 | Djupesland | Mar 2014 | A1 |
20140144442 | Djupesland et al. | May 2014 | A1 |
20140144443 | Djupesland et al. | May 2014 | A1 |
20140166008 | Djupesland | Jun 2014 | A1 |
20140202456 | Djupesland | Jul 2014 | A1 |
20140246022 | Djupesland et al. | Sep 2014 | A1 |
20150007811 | Djupesland et al. | Jan 2015 | A1 |
20150013670 | Djupesland et al. | Jan 2015 | A1 |
20150013677 | Djupesland et al. | Jan 2015 | A1 |
20150053201 | Djupesland et al. | Feb 2015 | A1 |
20150090259 | Djupesland et al. | Apr 2015 | A1 |
20150101605 | Djupesland et al. | Apr 2015 | A1 |
20150144129 | Djupesland et al. | May 2015 | A1 |
20150165139 | Hafner | Jun 2015 | A1 |
20150182709 | Djupesland | Jul 2015 | A1 |
20150246194 | Djupesland et al. | Sep 2015 | A1 |
20150367090 | Djupesland et al. | Dec 2015 | A1 |
20150367091 | Djupesland et al. | Dec 2015 | A1 |
20160001022 | Djupesland et al. | Jan 2016 | A1 |
20160045687 | Djupesland | Feb 2016 | A1 |
20160051778 | Djupesland et al. | Feb 2016 | A1 |
20160074603 | Djupesland et al. | Mar 2016 | A1 |
20160082206 | Djupesland et al. | Mar 2016 | A1 |
20160082207 | Djupesland et al. | Mar 2016 | A1 |
20160095989 | Djupesland | Apr 2016 | A1 |
20160095993 | Djupesland | Apr 2016 | A1 |
20160101249 | Djupesland | Apr 2016 | A1 |
20160166788 | Djupesland et al. | Jun 2016 | A1 |
20160184537 | Djupesland | Jun 2016 | A1 |
20160193435 | Djupesland | Jul 2016 | A1 |
20160250408 | Djupesland | Sep 2016 | A1 |
20160263334 | Djupesland | Sep 2016 | A1 |
20160279357 | Djupesland | Sep 2016 | A1 |
20160310683 | Djupesland et al. | Oct 2016 | A1 |
20160331916 | Djupesland et al. | Nov 2016 | A1 |
20160367771 | Djupesland | Dec 2016 | A1 |
20160367772 | Djupesland | Dec 2016 | A1 |
20160367774 | Djupesland et al. | Dec 2016 | A1 |
20170043108 | Djupesland et al. | Feb 2017 | A1 |
20170151397 | Djupesland | Jun 2017 | A1 |
20170203061 | Djupesland et al. | Jul 2017 | A1 |
20170216540 | Djupesland | Aug 2017 | A1 |
20170274164 | Djupesland et al. | Sep 2017 | A1 |
20170333649 | Djupesland | Nov 2017 | A1 |
Number | Date | Country |
---|---|---|
1 410 820 | Apr 2004 | EP |
2 378 393 | Feb 2003 | GB |
WO 9622802 | Aug 1996 | WO |
WO 9853869 | Dec 1998 | WO |
WO 0051672 | Sep 2000 | WO |
WO 0197689 | Dec 2001 | WO |
WO 02068029 | Sep 2002 | WO |
WO 02068030 | Sep 2002 | WO |
WO 02068031 | Sep 2002 | WO |
WO 02068032 | Sep 2002 | WO |
WO 03000310 | Jan 2003 | WO |
WO 03020350 | Mar 2003 | WO |
WO 03082393 | Oct 2003 | WO |
WO 03084591 | Oct 2003 | WO |
WO 03090812 | Nov 2003 | WO |
WO 2004004814 | Jan 2004 | WO |
WO 2004004922 | Jan 2004 | WO |
WO 2004060433 | Jul 2004 | WO |
WO 2004103447 | Dec 2004 | WO |
WO 2005016423 | Feb 2005 | WO |
WO 2005021059 | Mar 2005 | WO |
WO 2006030210 | Mar 2006 | WO |
WO 2006090149 | Aug 2006 | WO |
WO 2007083073 | Jul 2007 | WO |
WO 2007093784 | Aug 2007 | WO |
WO 2007093791 | Aug 2007 | WO |
WO 2007099361 | Sep 2007 | WO |
WO 2007102089 | Sep 2007 | WO |
WO 2007107887 | Sep 2007 | WO |
WO 2007125318 | Nov 2007 | WO |
WO 2007141541 | Dec 2007 | WO |
WO 2008012531 | Jan 2008 | WO |
WO 2008065403 | Jun 2008 | WO |
WO 2008081326 | Jul 2008 | WO |
WO 2008081327 | Jul 2008 | WO |
WO 2008122791 | Oct 2008 | WO |
WO 2008122795 | Oct 2008 | WO |
WO 2009044172 | Apr 2009 | WO |
WO 2010029441 | Mar 2010 | WO |
WO 2012035427 | Mar 2012 | WO |
WO 2012123819 | Sep 2012 | WO |
WO 2013124491 | Aug 2013 | WO |
WO 2013124492 | Aug 2013 | WO |
WO 2013124493 | Aug 2013 | WO |
WO 2014155192 | Oct 2014 | WO |
Entry |
---|
Cindy H. Dubin, Nothing to Sneeze At, Pharmaceutical Formulation & Quality Magazine (Jan. 29, 2003). |
Per Gisle Djupesland, Nasal Delivery of Vaccines, EPC (Jan. 29, 2003). |
Per Gisle Djupesland, Who Nose How Far Nasal Delivery Can Go?, EPC (Oct. 7, 2003). |
Per Gisle Djupesland, Bi-directional Nasal Drug Delivery, Innovations in Pharmaceutical Technology (Jul. 10, 2004). |
P.G. Djupesland, Bi-Directional Nasal Delivery of Aerosols Can Prevent Lung Deposition, Journal of Aerosol Medicine (Sep. 2004). |
Bi-Directional Nasal Device Delivers Drug on Exhalation, Pharmaceutical Technology (Sep. 10, 2004). |
Ola Dale et al., Intranasal Midazolam: A Comparison of Two Delivery Devices in Human Volunteers, Journal of Pharmacy and Pharmacology (Oct. 2004). |
G. Furness, Nasal Drug Delivery: Rapid Onset via a Convenient Route, ONdrugDelivery Ltd. (2005). |
M. Kleven, Using Computational Fluid Dynamics (CFD) to Improve the Bi-Directional Nasal Drug Delivery Concept, Trans IChemE Part C. (Jun. 2005). |
Per Gisle Djupesland, Breath-Actuated Bi-Directional Delivery Sets the Nasal Market on a New Course, ONdrugDelivery (Oct. 10, 2005). |
Hilde Bakke et al., Oral Spray Immunization May be an Alternative to Intranasal Vaccine Delivery to Induce Systemic Antibodies But Not Nasal Mucosal or Cellular Immunity, Scan J. of Immunol. (Mar. 2006). |
P.G. Djupesland et al., Breath Actuated Nasal Device Improves Delivery to Target Sites Beyond the Nasal Valve, The Laryngoscope (Mar. 2006). |
R. Luthringer et al., Rapid Absorption of Sumatriptan Powder and Effects on Glyceryl tinitrate Model of Headache Following Intranasal Delivery Using a Novel Bi-Directional Device, Journal of Pharmacy and Pharmacology (Jan. 2009). |
A. Skretting et al., A New Method for Scintigraphic Quantification of Deposition and Clearance in Anatomical Regions of the Human Nose, Nuclear Medicine Communications (Aug. 2009). |
Vlckovia et al., Effective Treatment of Mild-to-Moderate Nasal Polyposis with Fluticasone Delivered by a Novel Device, Rhinology (Oct. 22, 2009). |
Per Gisle Djupesland et al., Impact of Baseline Nasal Polyp Size and Previous Surgery on Efficacy of Fluticasone Delivered With a Novel Device: A Subgroup Analysis, Am. J. Rhinology Allergy (2010). |
P.G. Djupesland et al., Intranasal Sumatriptan Powder Delivered by a Novel Breath Actuated Bi-Directional Device for the Acute Treatment of Migraine: A Randomised Placebo-Controlled Study, Cephalalgia (Mar. 17, 2010). |
F.S. Hansen et al., Preliminary Efficacy of Fluticasone Delivered by a Novel Device in Recalcitrant Chronic Rhinosinusitis, Rhinology (Jun. 26, 2010). |
Per Gisle Djupesland, Nasal Drug Delivery Devices: Characteristics and Performance in Clinical Perspective—A Review, Drug. Deliv. and Transl. Res. (Oct. 18, 2012). |
Per Gisle Djupesland, Nasal Deposition and Clearance in Man: Comparison of a Bidirectional Powder Device and a Traditional Liquid Spray Pump, Journal of Aerosol Medicine and Pulmonary Drug Delivery (Nov. 2012). |
Stewart J. Tepper, Clinical Implications for Breath-Powered Powder Sumatriptan Intranasal Treatment, Headache, The American Headache Society (Apr. 29, 2013). |
Mohammad Obaidi et al., Improved Pharmacokinetics of Sumatriptan With Breath Powered Nasal Delivery of Sumatriptan Powder, Headache, The American Headache Society (May 24, 2013). |
Per Gisle Djupesland, Breath Powdered Nasal Delivery: A New Route to Rapid Headache Relief, Headache, The American Headache Society (Jun. 4, 2013). |
Per Gisle Djupesland et al., The Nasal Approach to Delivering Treatment for Brain Diseases: An Anatomic, Physiologic, and Delivery Technology Overview, Therapeutic Delivery (2014). |
R.K. Cady et al., A Randomized Double-Blind, Placebo Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study), Headache (Sep. 8, 2014). |
S.J. Tepper et al., AVP-825 Breath-Powdered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs. 100 mg Oral Sumatripta in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks, Headache: The Journal of Head and Face Pain (Mar. 29, 2015). |
D. S. Quintana et al., Low-dose Oxytocin Delivered Intranasally with Breath Powdered Device Affects Social-Cognitive Behavior: A Randomized Four-Way Crossover Trial with Nasal Cavity Dimension Assessment, Transl Psychiatry (Jul. 14, 2015). |
R. Mahmoud, Breathe Out, Innovations in Phar, Tech. (Dec. 10, 2015). |
Number | Date | Country | |
---|---|---|---|
20180311450 A1 | Nov 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12293972 | US | |
Child | 15001344 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15001344 | Jan 2016 | US |
Child | 15924536 | US |